Aim: Colorectal cancer (CRC) affects approximately one million people worldwide each year, with 500,000 deaths annually. In our country, CRC ranks as the third most common cancer in women and the fourth in men. Melatonin, a hormone with well-established antioxidant and anti-cancer properties, is produced by the pineal gland. Agomelatine, a recent addition to our antidepressant therapies, also acts on melatonin receptors and may offer therapeutic benefits in cancer treatment. This study investigates the effects of melatonin and agomelatine on the viability of human colorectal cancer cell lines (HCT-116 and Caco-2).
Materials and Methods: We treated HCT-116 and Caco-2 cell lines with melatonin and Agomelatine dissolved in 96% ethanol at concentrations of 0.1, 1, 5, and 10 mM for 24 hours. Cell viability was measured using 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolyum bromide (MTT) assay. Statistical analyses were performed using IBM SPSS Statistics 24.0, applying Bonferroni correction and the Mann-Whitney U-test, with significance set at p
Key words: Cancer, Melatonin, Agomelatine, HCT-116, Caco-2
|
